REGISTER
J&J Daratumumab SC Four-Drug Regimen Approved in China
Johnson & Johnson’s subcutaneous daratumumab has been approved in China as part of a four-drug regimen for transplant-eligible newly diagnosed multiple myeloma, backed by Phase III PERSEUS data showing significant improvements in progression-free survival and depth of response.

On February 6, Johnson & Johnson announced that its innovative therapy Darzalex Faspro—daratumumab injection (subcutaneous)—had received NMPA approval for an expanded indication, in combination with bortezomib, lenalidomide, and dexamethasone for adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation.

This means that patients may now receive a daratumumab subcutaneous formulation-based four-drug regimen as early as the newly diagnosed stage, gaining a new treatment option that significantly improves prognosis.

The approval was based on results from the Phase III PERSEUS study. In transplant-eligible newly diagnosed multiple myeloma, the trial compared a daratumumab SC-based four-drug regimen (DVRd) for induction and consolidation followed by daratumumab SC plus lenalidomide maintenance, versus induction and consolidation with bortezomib, lenalidomide, and dexamethasone (VRd) followed by lenalidomide maintenance.

With a median follow-up of 47.5 months, study data showed a significant improvement in the primary endpoint of progression-free survival (PFS). Compared with VRd, the DVRd regimen reduced the risk of disease progression or death by 58% (hazard ratio [HR] = 0.42; 95% confidence interval [CI]: 0.30–0.59; p < 0.0001).

In terms of depth of response, DVRd also showed significant advantages. The overall minimal residual disease (MRD) negativity rate at a sensitivity of 10⁻⁵ was 75.2%, higher than 47.5% in the VRd group (p < 0.0001). The proportion of patients achieving complete response or better was 87.9%, versus 70.1% in the VRd group (p < 0.0001). Importantly, 64.8% of patients achieved sustained MRD negativity lasting at least 12 months, significantly above the 29.7% seen with VRd.

Clinical manifestations vary greatly among patients with multiple myeloma, and first-line treatment is the key stage for achieving the deepest response and longest survival. Innovative therapies that can significantly delay disease progression are urgently needed. Supported by strong evidence, the daratumumab SC-based four-drug regimen offers a transformative new option for clinical practice and shows potential to deepen response and prolong remission in transplant-eligible patients.

The overall safety profile of DVRd was consistent with the known safety profiles of daratumumab SC and the VRd regimen. The most common hematologic adverse reactions (incidence ≥20%) included neutropenia, thrombocytopenia, and anemia. The most common non-hematologic adverse reactions included peripheral neuropathy, fatigue, peripheral edema, pyrexia, upper respiratory tract infection, COVID-19, constipation, diarrhea, back pain, insomnia, asthenia, and rash.

0
0
Loading